These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18394961)

  • 1. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
    Ito K; Caramori G; Adcock IM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):1-8. PubMed ID: 17021257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.
    Marwick JA; Chung KF; Adcock IM
    Ther Adv Respir Dis; 2010 Feb; 4(1):19-34. PubMed ID: 20051446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biological effects of isoform-specific PI3-kinase inhibition.
    Ihle NT; Powis G
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):41-9. PubMed ID: 20047145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
    Park SJ; Min KH; Lee YC
    Respirology; 2008 Nov; 13(6):764-71. PubMed ID: 18811876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
    Wee S; Lengauer C; Wiederschain D
    Curr Opin Oncol; 2008 Jan; 20(1):77-82. PubMed ID: 18043260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping and distinct roles for PI3Kbeta and gamma isoforms in S1P-induced migration of human and mouse endothelial cells.
    Heller R; Chang Q; Ehrlich G; Hsieh SN; Schoenwaelder SM; Kuhlencordt PJ; Preissner KT; Hirsch E; Wetzker R
    Cardiovasc Res; 2008 Oct; 80(1):96-105. PubMed ID: 18558630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.
    Doukas J; Wrasidlo W; Noronha G; Dneprovskaia E; Hood J; Soll R
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):204-6. PubMed ID: 17371238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
    Fougerat A; Gayral S; Malet N; Briand-Mesange F; Breton-Douillon M; Laffargue M
    Clin Sci (Lond); 2009 May; 116(11):791-804. PubMed ID: 19397491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
    Sturgeon SA; Jones C; Angus JA; Wright CE
    Eur J Pharmacol; 2008 Jun; 587(1-3):209-15. PubMed ID: 18455722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening.
    Frédérick R; Mawson C; Kendall JD; Chaussade C; Rewcastle GW; Shepherd PR; Denny WA
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5842-7. PubMed ID: 19748269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemically targeting the PI3K family.
    Knight ZA; Shokat KM
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):245-9. PubMed ID: 17371250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac regulation by phosphoinositide 3-kinases and PTEN.
    Oudit GY; Penninger JM
    Cardiovasc Res; 2009 May; 82(2):250-60. PubMed ID: 19147653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?
    Rückle T; Schwarz MK; Rommel C
    Nat Rev Drug Discov; 2006 Nov; 5(11):903-18. PubMed ID: 17080027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taming the PI3K team to hold inflammation and cancer at bay.
    Hirsch E; Ciraolo E; Ghigo A; Costa C
    Pharmacol Ther; 2008 May; 118(2):192-205. PubMed ID: 18420279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
    Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
    Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Rommel C; Camps M; Ji H
    Nat Rev Immunol; 2007 Mar; 7(3):191-201. PubMed ID: 17290298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide 3-kinase signalling in the vascular system.
    Morello F; Perino A; Hirsch E
    Cardiovasc Res; 2009 May; 82(2):261-71. PubMed ID: 19038971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K inhibitors in cardiovascular disease.
    Eisenreich A; Rauch U
    Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.